Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel
OTCMKTS:ZLDPF

Zealand Pharma A/S Q2 2024 Earnings Report

Zealand Pharma A/S logo
$44.70 0.00 (0.00%)
As of 06/12/2026
ProfileEarnings HistoryForecast

Zealand Pharma A/S EPS Results

Actual EPS
-$0.67
Consensus EPS
-$0.61
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

Zealand Pharma A/S Revenue Results

Actual Revenue
$4.93 million
Expected Revenue
$0.50 million
Beat/Miss
Beat by +$4.43 million
YoY Revenue Growth
N/A

Zealand Pharma A/S Announcement Details

Quarter
Q2 2024
Date
8/15/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Zealand Pharma A/S' next earnings date is estimated for Thursday, August 13, 2026, based on past reporting schedules.

Conference Call Resources

Zealand Pharma A/S Earnings Headlines

Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)
June 15 at 11:31 AM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma---transactions-related-to-share-buy-back-program-week-24-2026-1036249982
Drugmakers race to find a place in the next wave of obesity drugs
June 13 at 8:00 AM  |  cnbc.comhttps://www.cnbc.com/2026/06/13/glp-1s-lilly-novo-pfizer-look-to-new-weight-loss-drugs.html
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
June 15 at 1:00 AM  |  InvestorPlace (Ad)
Roche and Zealand Advance Combo Obesity Drug Trial, Signaling New Momentum for ZLDPF
June 12 at 12:51 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/roche-and-zealand-advance-combo-obesity-drug-trial-signaling-new-momentum-for-zldpf?utm_source=marketbeat.com&utm_medium=referral
Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)
June 8, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma---transactions-related-to-share-buy-back-program-week-23-2026-1036232504
Zealand Pharma Shares Slide After Boehringer Study Shows Obesity Shot's Side Effects
June 8, 2026  |  wsj.comhttps://www.wsj.com/health/pharma/zealand-pharma-shares-slide-after-boehringer-study-shows-obesity-shots-side-effects-a624e7b4
See More Zealand Pharma A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zealand Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zealand Pharma A/S and other key companies, straight to your email.

About Zealand Pharma A/S

Zealand Pharma A/S (OTCMKTS:ZLDPF) is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia. The company is also developing glepaglutide, a long‐acting GLP-2 analog for the management of short bowel syndrome, with ongoing clinical trials assessing its ability to reduce parenteral support dependency. Zealand has entered strategic collaborations with leading pharmaceutical firms to co‐develop and commercialize select programs, leveraging global regulatory and commercial expertise to accelerate patient access.

Founded in 1998 and headquartered in Copenhagen, Zealand Pharma conducts research and development activities in Scandinavia while maintaining partnerships and licensing agreements that extend its reach to markets in Europe, North America and Asia. The company’s leadership, including CEO Emmanuel Dulac, brings together expertise in peptide science, clinical development and corporate strategy. Zealand Pharma’s dual listing on the Copenhagen Stock Exchange and OTC markets in the U.S. underscores its commitment to broad investor engagement and global growth.

View Zealand Pharma A/S Profile
Earnings Tools